Zevra Therapeutics (ZVRA) reported a Q1 net loss late Tuesday of $0.06 per diluted share, narrowing from the loss of $0.40 a year earlier.

Analysts polled by FactSet expected a loss of $0.19.

Net revenue in the three months ended March 31 rose to $20.4 million from $3.43 million a year earlier.

Analysts surveyed by FactSet expected $16.9 million.

Zevra shares rose 4.8% in after-hours trading.